What Is New Dietary Ingredient?

A dietary ingredient that was not marketed in the United States before October 15, 1994. Manufacturers must submit a pre-market safety notification (NDI notification) to the FDA at least 75 days before marketing a supplement containing an NDI.

Why It Matters for Supplement Brands

If your product contains an ingredient that wasn't sold as a supplement before DSHEA's enactment date, you're legally required to file an NDI notification. Failure to do so can result in FDA warning letters and product seizures — even if the ingredient is perfectly safe.

How It Works

The NDI notification process requires:

1. **Determination**: Establish whether your ingredient qualifies as 'new' (not marketed before October 15, 1994). 2. **Safety evidence**: Compile evidence demonstrating the ingredient is 'reasonably expected to be safe' at the proposed dose. 3. **75-day notification**: Submit the notification to the FDA at least 75 days before first marketing. 4. **FDA response**: The FDA may object, request more data, or allow the 75-day period to expire without objection.

The FDA maintains a public database of all NDI notifications and their responses, which can be a useful research tool for brands evaluating new ingredients.

Common Mistakes to Avoid

  • Not checking whether your ingredient qualifies as an NDI before launching
  • Relying on a supplier's claim that 'no NDI notification is needed' without independent verification
  • Submitting insufficient safety evidence, leading to FDA objection
  • Confusing GRAS (Generally Recognized as Safe) status for food with NDI requirements for supplements

Related Terms

DSHEA (Dietary Supplement Health and Education Act)cGMP (Current Good Manufacturing Practices)

See It in Action

Explore how this concept applies to real ingredient substantiation:

Collagen Peptides
41 studies · Skin Health
NAC (N-Acetyl Cysteine)
53 studies · Antioxidant & Detoxification

Automate Your Substantiation

Nutra Comp turns weeks of manual research into minutes of automated clinical evidence analysis and FDA-compliant claim generation.

Join the Waitlist